NEPHRON PHARMACEUTICALS CORPORATION

Lobbying client · South Carolina · filed 2025 to 2026

Developer and manufacturer of sterile inhalation and 503B outsourcing medication.

$240,000 Reported spend

7 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page is grouped by the client's LDA id (202541), not by name.

Firms hired 1

THE VOGEL GROUP $240,000 7 filings

Reported by year 2 years

2026 $100,000 2 filings
2025 $140,000 5 filings

Issues lobbied 1

Pharmacy 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

Health & Human Services, Dept of (HHS) 5
Food & Drug Administration (FDA) 1

Recent filings 7 total

Q2

THE VOGEL GROUP

2nd Quarter (Apr 1 - June 30) 2026 · $50,000 income · posted Jul 19, 2026

View → Q1

THE VOGEL GROUP

1st Quarter (Jan 1 - Mar 31) 2026 · $50,000 income · posted Apr 20, 2026

View → Q4

THE VOGEL GROUP

4th Quarter (Oct 1 - Dec 31) 2025 · $50,000 income · posted Jan 19, 2026

View → Q3

THE VOGEL GROUP

3rd Quarter (July 1 - Sep 30) 2025 · $45,000 income · posted Oct 19, 2025

View → Q2

THE VOGEL GROUP

2nd Quarter (Apr 1 - June 30) 2025 · $45,000 income · posted Jul 20, 2025

View → Q1Y

THE VOGEL GROUP

1st Quarter (Jan 1 - Mar 31) 2025 · posted Apr 20, 2025

View → RA

THE VOGEL GROUP

2nd Quarter (Apr 1 - June 30) 2025 · posted Apr 7, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.